Design	design	O	O	O	O
and	and	O	O	O	O
analysis	analysis	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
HYPREN-trial	hypren-trial	O	O	O	O
:	:	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
prazosin	prazosin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
initial	initial	O	O	O	O
treatment	treatment	O	O	O	O
phase	phase	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Since	since	O	O	O	O
the	the	O	O	O	O
introduction	introduction	O	O	O	O
of	of	O	O	O	O
angiotensin	angiotensin	CHEMICALS	O	OTHERS	I
converting	converting	O	O	OTHERS	I
enzyme	enzyme	O	O	OTHERS	I
(	(	O	O	OTHERS	I
ACE	ace	O	O	OTHERS	I
)	)	O	O	OTHERS	I
inhibitors	inhibitors	O	O	OTHERS	I
into	into	O	O	O	O
the	the	O	O	O	O
adjunctive	adjunctive	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
,	,	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
especially	especially	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
have	have	O	O	O	O
occasionally	occasionally	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
ACE	ace	CHEMICALS	O	OTHERS	I
inhibitor	inhibitor	CHEMICALS	O	OTHERS	I
enalapril	enalapril	CHEMICALS	O	OTHERS	I
a	a	O	O	O	O
multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
prazosin-controlled	prazosin-controlled	O	O	O	O
trial	trial	O	O	O	O
was	was	O	O	O	O
designed	designed	O	O	O	O
that	that	O	O	O	O
compared	compared	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
and	and	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
symptomatic	symptomatic	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
on	on	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Trial	trial	O	O	O	O
medication	medication	O	O	O	O
was	was	O	O	O	O
2.5	2.5	O	O	O	O
mg	mg	O	O	OTHERS	I
enalapril	enalapril	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
0.5	0.5	O	O	O	O
prazosin	prazosin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Subjects	subjects	O	O	O	O
were	were	O	O	O	O
1210	1210	O	O	O	O
inpatients	inpatients	O	O	O	O
with	with	O	O	O	O
New	new	O	O	O	O
York	york	O	O	O	O
Heart	heart	O	O	O	O
Association	association	O	O	O	O
(	(	O	O	O	O
NYHA	nyha	O	O	O	O
)	)	O	O	O	O
functional	functional	O	O	O	O
class	class	O	O	O	O
II	ii	O	O	O	O
and	and	O	O	O	O
III	iii	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
experienced	experienced	O	O	O	O
clinically	clinically	O	O	O	O
and	and	O	O	O	O
statistically	statistically	O	O	O	O
significantly	significantly	O	O	O	O
less	less	O	O	O	O
symptomatic	symptomatic	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
(	(	O	O	O	O
5.2	5.2	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
prazosin	prazosin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
12.9	12.9	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
recovered	recovered	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
was	was	O	O	O	O
concluded	concluded	O	O	O	O
that	that	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
and	and	O	O	O	O
it	it	O	O	O	O
is	is	O	O	O	O
,	,	O	O	O	O
therefore	therefore	O	O	O	O
,	,	O	O	O	O
unreasonable	unreasonable	O	O	O	O
to	to	O	O	O	O
restrict	restrict	O	O	O	O
the	the	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
enalapril	enalapril	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
inpatients	inpatients	O	O	O	O
.	.	O	O	O	O

